Magle Chemoswed

Bifogade filer

Q1 2025 Interim Report Final

Kurs

-3,05%

Likviditet

0,20 MSEK

Prenumeration

Kalender

	Est. tid*
2026-02-27	08:30	Bokslutskommuniké 2025
2025-11-14	07:30	Kvartalsrapport 2025-Q3
2025-08-01	-	Kvartalsrapport 2025-Q2
2025-05-27	-	X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26	-	Årsstämma
2025-05-22	-	Kvartalsrapport 2025-Q1
2025-03-27	-	Bokslutskommuniké 2024
2024-12-30	-	Extra Bolagsstämma 2025
2024-10-24	-	Kvartalsrapport 2024-Q3
2024-10-04	-	Extra Bolagsstämma 2024
2024-07-18	-	Kvartalsrapport 2024-Q2
2024-04-26	-	X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25	-	Årsstämma
2024-04-18	-	Kvartalsrapport 2024-Q1
2024-02-16	-	Bokslutskommuniké 2023
2023-10-25	-	Kvartalsrapport 2023-Q3
2023-07-18	-	Kvartalsrapport 2023-Q2
2023-04-27	-	X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26	-	Årsstämma
2023-02-16	-	Bokslutskommuniké 2022
2022-11-09	-	Kvartalsrapport 2022-Q3
2022-08-17	-	Kvartalsrapport 2022-Q2
2022-05-19	-	X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17	-	Årsstämma
2022-05-05	-	Kvartalsrapport 2022-Q1
2022-02-25	-	Bokslutskommuniké 2021
2021-12-14	-	Extra Bolagsstämma 2021
2021-11-16	-	Kvartalsrapport 2021-Q3
2021-08-17	-	Kvartalsrapport 2021-Q2
2021-05-14	-	Kvartalsrapport 2021-Q1
2021-05-03	-	X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18	-	Årsstämma
2021-02-25	-	Bokslutskommuniké 2020
2020-11-27	-	Extra Bolagsstämma 2020
2020-11-05	-	Kvartalsrapport 2020-Q3
2020-07-14	-	Kvartalsrapport 2020-Q2

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Medicinteknik

Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Magle Chemoswed Holding Reports Financial Results For First Quarter 2025

2025-05-22 09:56:00

Magle Group's Q1 report highlights a continuation of steady revenue growth in DSM and CDMO, with increased clinical partnerships. Planned strategic investments in 2025 are set to enhance the company’s operational efficiency and drive sustained profitability over the long term.

Q1 2025 KEY INDICATORS

Revenues amounted to 85.1 MSEK (42.3)
EBITDA equaled 18.8 MSEK (7.1)
Operating profit (EBIT) is 2.1 MSEK (4.2)
Earnings per share SEK -0,07 (0,27) per share

” In the first quarter, Magle Group made strides through establishing its two new business units: Magle Biopolymers and Magle Biopharma. Additionally, we maintained robust organic growth in both the DSM segment and CDMO operations. Increased project requests, stronger client relationships, and clinical collaborations propelled our expansion into dextran-based biopolymers and amniotic mesenchymal stem cells.” says Justin Pierce, CEO

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Magle Chemoswed

Bifogade filer

Kurs -3,05%

Likviditet 0,20 MSEK